Toxicity and Safety Evaluation of an Omega-3 Fatty Acid and a Multivitamin and Antioxidant Nutritional Preparation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and tolerability of two supplements in healthy subjects taken daily for six months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Supplementation With Omega-3: Mechanism of Action

NCT02036307

Hypertriglyceridemia

TERMINATED PHASE2

Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors

NCT00930527

Breast Cancer

TERMINATED PHASE2

An Evaluation of Omega-3 Fatty Acid

NCT03017651

Overweight and Obesity

COMPLETED PHASE1

Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease

NCT04088240

Elevated Triglycerides Cardiovascular Risk Factor

TERMINATED NA

Fish Oil and Cardiovascular Suboptimal Health

NCT02103517

Suboptimal Health Status

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Lyndon B. Johnson Space Center (JSC) of the National Aeronautics and Space Administration (NASA) and AmeriSciences have entered into a Space Act Agreement (1), the primary objectives of which are the development of nutritional products in the form of dietary supplements to maintain homeostasis, and as countermeasures to reduce the biological effects and damages of long-duration spaceflight mediated through oxidative stress both in low Earth Orbit and planetary exploration of the solar system, as well as to provide optimal nutritional supplementation to aid in pre-spaceflight conditioning.

NASA has determined through pre-, in-, and post-flight assessment of cells, animals and humans that spaceflight induces oxidative stress on crewmembers. There are multiple potential sources of oxidative injury to include, but not limited to space radiation, noise, fuel reaction products, planetary regolith, and exercise. Furthermore, NASA has also determined that several foreseen and unforeseen physiological events can be controlled, avoided, or encouraged by means of dietary modification through supplements. Due to unforeseen limitation in the available fresh food supply for envisioned exploratory missions, it is desirable for NASA to have nutritional supplementation available to provide crewmembers with augmentation for the intrinsic defense systems against oxidative damage, as well as for potential nutritional contingencies such as food shortages and optimization of the diet. NASA has identified the need for specific micronutrient formulations to complement natural food sources, for astronaut protection during long-duration space flight.

AmeriSciences is a nutritional company that specializes in science-based product formulation, manufacturing under Good Manufacturing Practices (GMP) using standards modeled after those used by the pharmaceutical industry. It has been charged with the co-development, aid, clinical evaluation, construction, and production of said micronutrient formulations, to the level of specifications required to meet NASA's expectations for safety and efficacy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active/Placebo

ACTIVE VITAMIN; PLACEBO OMEGA MAX

No interventions assigned to this group

Active/Active

ACTIVE VITAMIN; ACTIVE OMEGA MAX

No interventions assigned to this group

Placebo/Active

PLACEBO VITAMIN; ACTIVE OMEGA MAX

No interventions assigned to this group

Placebo/Placebo

PLACEBO VITAMIN; PLACEBO OMEGA MAX

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be eligible, patients must meet the following eligibility criteria:

1. Male or Female subject between the ages of 21 and 65 years
2. Capable of providing informed consent
3. Patients currently taking HMG-CoA reductase inhibitors (i.e. "statin" drugs), or any other drug known to interfere with serum transaminase (i.e. liver enzymes), must have history of stable liver function test since first taking such drugs.
4. Patients who usually and customarily take dietary supplements, including vitamins, must undergo a two-week washout period

Exclusion Criteria

1. Exposure to any investigational drug within 90 days of the beginning of this study
2. Known human immunodeficiency virus (HIV) seropositivity or Acquired Immunodeficiency Syndrome (AIDS); history of Hepatitis B (HBV), Hepatitis C (HCV) vital infection, unexplained elevated serum transaminase, or other hepatic disease. NOTE: HIV, HCV and HBV testing will not be performed as part of screening.
3. History of cancer within the last 5 years, except for basal or squamous cell cancer.
4. Allergy to fish (specifically sardines, anchovies or mackerel) or any of the investigational product components
5. Concomitant use, or use within less than a two-week period, of any other dietary supplement
6. Concomitant use of any drug known to interfere with laboratory measures such as:

1. Niaspan (extended release niacin)
2. Lamisil (terbinafine HCl)
3. Chronic use of acetaminophen (\>1,500 mg/day) (occasional use for minor aches and pains is excluded from this restriction)
4. New prescriptions (\< 90days) of HMG-CoA reductase inhibitors ("statins"), or patients currently on statins who have previously shown evidence of elevated serum transaminases
7. Currently diagnosed with multiple sclerosis, systemic lupus erythematosis, or other autoimmune disorders known to interfere with laboratory measures
8. Pregnancy, Lactation, or females actively attempting to become pregnant
9. History of alcoholism or drug abuse, unless it is determined that such past use would not influence laboratory measures (DSN4 criteria)
10. Any other active disease of a life-threatening nature or laboratory abnormality that, in the judgment of the investigator, may interfere with the interpretation, or increase risk of patient participation
11. Conditions that require nutritional therapy, such as:

1. Pernicious anemia
2. Iron-deficiency anemia
3. Hartnup Disease or Pellagra
4. Scurvy
5. Beriberi-induced Endemic Neuritis

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes